Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats.

Autor: Yano T; Research Center, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan., Ito T; Graduate School of Photonics Science, Chitose Institute of Science and Technology, 758-65 Bibi, Chitose, Hokkaido 066-8655, Japan., Kanehira Y; Graduate School of Photonics Science, Chitose Institute of Science and Technology, 758-65 Bibi, Chitose, Hokkaido 066-8655, Japan., Yamada M; Research Center, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan., Kimura-Suda H; Graduate School of Photonics Science, Chitose Institute of Science and Technology, 758-65 Bibi, Chitose, Hokkaido 066-8655, Japan., Wagatsuma H; Research Center, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan., Inoue D; Third Department of Medicine, Teikyo University School of Medicine, 3426-3 Anegasaski, Ichihara-shi, Chiba 299-0111, Japan.
Jazyk: angličtina
Zdroj: Bone reports [Bone Rep] 2021 Apr 06; Vol. 14, pp. 101061. Date of Electronic Publication: 2021 Apr 06 (Print Publication: 2021).
DOI: 10.1016/j.bonr.2021.101061
Abstrakt: Combination therapy of active vitamin D 3 with some bisphosphonates (BPs) has been reported to be clinically beneficial. However, combination therapy of eldecalcitol (ELD) with BP has to date not been validated as to whether it is beneficial in the clinical setting. Preclinical studies suggested that simultaneous treatment with ELD and some BPs is more effective than monotherapy. However, the relative potency of various BPs, when used in combination with ELD, is completely unknown. In this study, we examined and compared the effects of risedronate (RIS), alendronate (ALN), and minodronate (MIN) alone or in combination with ELD on bone mass, microarchitecture, strength, and material properties in ovariectomized Sprague-Dawley rats aged 13 weeks. RIS, ALN, MIN, and ELD were administered five times weekly for 16 weeks. Micro-computed tomography analysis, compression test, and Fourier transform infrared (FTIR) imaging analysis were performed 16 weeks after treatment initiation. Trabecular and cortical bone mineral density (BMD) in the fourth lumbar vertebra (L4) significantly increased in the RIS + ELD, ALN + ELD, and MIN + ELD groups compared with the vehicle group. Moreover, the bone microarchitecture of L4 in all the BP + ELD groups also significantly improved. On mechanical testing of L4, the maximum load was significantly increased in the RIS + ELD and ALN + ELD groups. FTIR analysis revealed that the mineral-to-collagen ratio of trabecular bone in L3 of all the BP + ELD groups was significantly increased compared with the vehicle group. By contrast, the carbonate-to-phosphate ratio, a parameter of mineral immaturity, was significantly decreased in the RIS + ELD and ALN + ELD groups. BP + ELD improved the BMD and structural properties of the bone to a similar extent. RIS + ELD and ALN + ELD also improved bone strength. Furthermore, treatment with BP + ELD improved the bone material. These results suggest that the combination therapy of BP and ELD is beneficial and warrants further clinical trials.
Competing Interests: The authors declare that they have no conflict of interest in this study. HK has received research funding from 10.13039/100014421EA pharma (formerly known as Ajinomoto Pharmaceutical). DI has received honoraria and research funding from 10.13039/501100004948Astellas Pharma, 10.13039/100002429Amgen, 10.13039/100014421EA Pharma, 10.13039/100010795Chugai Pharmaceutical, 10.13039/501100002336Daiichi Sankyo, Taisyo Pharmaceutical, and 10.13039/501100010486Teijin Pharma.
(© 2021 The Author(s).)
Databáze: MEDLINE
Externí odkaz: